Joshua A Epstein, 84132 Valley Club Cir, Little Rock, AR 72212

8318297, Nov 27, 2012

Jun 25, 2008

12/146139

Joshua Epstein - Little Rock AR, US

Board of Trustees of the University of Arkansas - Little Rock AR

B32B 3/26

4283044, 4283066, 4283073, 428364, 428372, 428401, 428402, 977762, 977763

In one aspect, the present invention relates to a synthetic nanostructure. In one embodiment, the synthetic nanostructure has a top region substantially comprising titanate nanowires, a middle region substantially comprising titanate nanoparticles and titanate nanowires, and a bottom region substantially comprising titanium, wherein some of the titanate nanowires of the top region are extending into the middle region, wherein the middle region is between the top region and the bottom region, and wherein some of the titanate nanowires of the top region are substantially perpendicular to the bottom surface of the titanium substrate. At least some of the titanate nanowires in the top region form 3D macroporous scaffolds with interconnected macropores.

2011026, Nov 3, 2011

Apr 29, 2011

13/068008

Joshua Epstein - Little Rock AR, US
Shmuel Yaccoby - Little Rock AR, US
Barthel Barlogie - Little Rock AR, US
Igor Entin - Little Rock AR, US

C40B 30/04
G06F 19/12
C40B 60/12

506 9, 506 39, 702 19

Provided are methods, systems and kits for predicting post-relapse survival of a cancer patient and for identifying cancer genes predictive of the post-relapse survival of the patient. Values representing gene expression levels of a group of genes associated with survival of the cancer cells are determined using gene expression profiling platforms and a plurality of probe sets that hybridize to one or more of the genes in the group. A predictive model establishes a predictive value based on the weighted contribution of each gene associated with survival of the cancer cells to risk of death for the cancer patient and imports expression values of the genes in the group that is indicative of a risk of death for the relapsed patient. Using global gene expression profiling and statistical analysis, expression of cancer cell genes at baseline and at first relapse that are involved in interaction of cancer cells with cells in their microenvironment, can be used to identify genes that are predictive of post-relapse survival.

2014007, Mar 20, 2014

Apr 27, 2012

14/114406

Joshua Epstein - Little Rock AR, US
Shmuel Yaccoby - Little Rock AR, US
Barthel Barlogie - Little Rock AR, US
Igor Entin - Little Rock AR, US

C12Q 1/68
A61K 31/704
A61K 31/573
A61K 33/24
A61K 31/454
A61K 31/4965

424649, 435 612, 506 9, 514323, 51425506, 514171

Provided are methods, systems and kits for predicting post-relapse survival of a cancer patient and for identifying cancer genes predictive of the post-relapse survival of the patient. Values representing gene expression levels of a group of genes associated with survival of the cancer cells are determined using gene expression profiling platforms and a plurality of probe sets that hybridize to one or more of the genes in the group. A predictive model establishes a predictive value based on the weighted contribution of each gene associated with survival of the cancer cells to risk of death for the cancer patient and imports expression values of the genes in the group that is indicative of a risk of death for the relapsed patient. Using global gene expression profiling and statistical analysis, expression of cancer cell genes at baseline and at first relapse that are involved in interaction of cancer cells with cells in their microenvironment, can be used to identify genes that are predictive of post-relapse survival.

2020039, Dec 17, 2020

Aug 24, 2020

17/001173

- Little Rock AR, US
Pingping QU - Little Rock AR, US
Christoph HEUCK - Little Rock AR, US
Joshua EPSTEIN - Little Rock AR, US

BioVentures, LLC - Little Rock AR

C12Q 1/6886
G16B 25/00

The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.

2018017, Jun 21, 2018

Nov 17, 2017

15/816463

- Little Rock AR, US
Pingping Qu - Litttle Rock AR, US
Christoph Heuck - Litttle Rock AR, US
Joshua Epstein - Little Rock AR, US

BioVentures, LLC - Little Rock AR

C12Q 1/6886
G06F 19/20

The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.

2016010, Apr 14, 2016

May 19, 2014

14/892555

- Little Rock AR, US
Pingping QU - Little Rock AR, US
Christoph HEUCK - Little Rock AR, US
Joshua EPSTEIN - Little Rock AR, US

C12Q 1/68
G06F 19/20

The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP 13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.